Paper Details

  1. Home
  2. Paper Details

Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.

Author: AaproMatti, GrallaRichard J, HeskethPaul J, JordanKarin, PalmasMarco, RizziGiada, RossiGiorgia

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This analysis documented the safety profile of netupitant and palonosetron plus dexamethasone, a fixed combination therapy, in comparison with current therapies for chemotherapy-induced nausea and vomiting. The combination showed a favorable cardiac safety profile.
Paper Details　
Original Abstract of the Article :
Standard prophylaxis for chemotherapy-induced nausea and vomiting (CINV) with highly emetogenic and anthracycline-cyclophosphamide-based chemotherapy includes a 5-hydroxytryptamine-3 receptor antagonist, a neurokinin-1 receptor antagonist (NK1RA), and corticosteroid therapy. NEPA is a fixed combinat...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4828115/

データ提供：米国国立医学図書館（NLM）

NEPA: A New Approach to Combating Chemotherapy-Induced Nausea and Vomiting

Chemotherapy, while a powerful weapon against cancer, often comes with unpleasant side effects. One of the most common and debilitating side effects is chemotherapy-induced nausea and vomiting (CINV). This research focuses on the safety and efficacy of NEPA, a fixed combination of netupitant and palonosetron, for preventing CINV. The researchers analyzed pooled data from phase II/III clinical trials to assess the safety profile of NEPA in comparison to existing therapies.

A New Combination Shows Promise for CINV Prevention

The analysis showed that NEPA, in combination with dexamethasone, demonstrated a favorable safety profile comparable to existing standard therapies for CINV prevention. This suggests that NEPA could be a valuable addition to the arsenal of tools for combating this debilitating side effect of chemotherapy.

Easing the Burden of Chemotherapy

NEPA’s safety and efficacy could potentially lead to better management of CINV, improving the quality of life for cancer patients undergoing chemotherapy. It’s like finding a new, more comfortable camel to ride across the desert – smoother and more comfortable for the journey ahead.

Dr.Camel's Conclusion

NEPA shows promise as a safe and effective treatment for CINV. It’s like finding a new, more comfortable oasis in the desert – a place of respite and relief for those enduring the challenges of chemotherapy.

Date :
  1. Date Completed 2016-12-23
  2. Date Revised 2020-12-09
Further Info :

Pubmed ID

27000465

DOI: Digital Object Identifier

PMC4828115

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.